CRISPR Therapeutics reports trial results for CAR-T treatment
CRISPR Therapeutics presented early Phase 1 data on an off-the-shelf cell therapy for autoimmune conditions, including inflammatory muscle disease and scleroderma, at a rheumatology meeting.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
What happened
CRISPR Therapeutics reported Phase 1 trial data for its off-the-shelf CAR-T therapy zugocabtagene geleucel. In refractory scleroderma, 83% of patients showed a clinical response with no graft-versus-host disease.
Why it matters
Dose escalation of the trial is continuing.
Timeline
- Nov 8, 10:30 AM ET: CRISPR Therapeutics reported that all nine patients with inflammatory muscle disease met response measures, with no CRS above Grade 2 or ICANS among 21 patients.
- Nov 8, 10:30 AM ET: Six patients given 200 million CAR+ cells showed higher expansion than those given 100 million, and dose escalation continues.
- Nov 9, 9:21 PM ET: An 83% clinical response rate with zero graft-versus-host disease was reported in refractory scleroderma, per Phase 1 data presented at ACR Convergence 2026.
Coverage
- Off-the-Shelf CRISPR CAR-T Hits 83% Response in Scleroderma Without Triggering Graft-Versus-Host Disease (Donald C. Case)
- All 9 patients with inflammatory muscle disease met response measures in CRISPR Therapeutics' trial (CRISPR Therapeutics AG)
More from Science
- SpaceX plans Starship Flight 15 with double catch attempt
- Researchers find gravity may break and reconnect in Einstein's equations
- Researchers say Trump-era cuts push scientists out of U.S
- California voters approve $8.4 billion immunology research bond
- Study finds one degree of warmth can shift alligator sex
- Scientists use machine learning to trace fish schooling's evolution